Kura Oncology (KURA) Tax Provisions (2025 - 2026)
Kura Oncology's (KURA) quarterly Tax Provisions came in at $8000.0 in Q1 2026, down 96.46% year-on-year from $226000.0 in Q1 2025, and down 88.73% on a QoQ basis from $71000.0 in Q4 2025.
Kura Oncology (KURA) Tax Provisions (2025 - 2026) Analysis & Trends
Kura Oncology (KURA) has 2 years of Tax Provisions data on file, last reported at $8000.0 in Q1 2026.
- On a quarterly basis, Tax Provisions fell 96.46% year-over-year to $8000.0 in Q1 2026; TTM through Mar 2026 was $79000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $297000.0, up 3.48% from the prior year.
- Tax Provisions for Q1 2026 stood at $8000.0, down from $71000.0 in the prior quarter.
- Over the last five years, Tax Provisions for KURA reached as high as $226000.0 in Q1 2025 and fell as low as $8000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 125,146.46 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -859,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 31.86 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 221.50 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -60.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Kura Oncology | 928.19 Mn | 928.19 Mn | 18.00 Mn | 8,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8,000.00 |
| Dec 31, 2025 | 71,000.00 |
| Mar 31, 2025 | 226,000.00 |